Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30169480 | 1.00 | ADRB2 (0.44) | ADRB2HIF1AADRB1CYP1A2CYP2D6 | |
| Sulfuric Acid SCHEMBL2524101 | 0.92 | PMP22 (0.50) | ADRB2HIF1AADRB1CYP1A2CYP2D6 | |
| Sulfuric Acid SCHEMBL21825446 | 0.92 | PMP22 (0.50) | ADRB2HIF1AADRB1CYP1A2CYP2D6 | |
| SCHEMBL3136060 | 0.83 | ADRB2 (0.42) | ADRB2HIF1AADRB1CYP1A2CYP2D6 | |
| SCHEMBL30254390 | 0.80 | PMP22 (0.40) | ADRB2HIF1AADRB1CYP1A2CYP2D6 | |
| Water SCHEMBL28944323 | 0.79 | PMP22 (0.39) | ADRB2HIF1AADRB1CYP1A2CYP2D6 | |
| SCHEMBL4258634 | 0.79 | CYP2D6 (0.47) | ADRB2HIF1AADRB1CYP1A2CYP2D6 | |
| SCHEMBL207165 | 0.77 | KDM4E (0.41) | CYP1A2TSHRTDP1KLF10LMNA | |
| SCHEMBL11278988 | 0.76 | HIF1A (0.40) | ADRB2HIF1AADRB1CYP1A2CYP2D6 | |
| SCHEMBL9873217 | 0.73 | ADRB2 (0.38) | ADRB2HIF1AADRB1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-04-11 | — | — | US | claimed |
| US-10799599-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-04-11 | — | — | US | disclosed |
| US-10207008-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10159752-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-10117940-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| EP-3238708-A1 | INHALANT FORMULATION CONTAINING CYCLODEXTRIN AND CORTICOSTEROID | CyDex Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-8623851-B2 | Formoterol/steroid bronchodilating compositions and methods of use thereof | MYLAN SPECIALTY L.P. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130303498-A1 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2013-11-14 | — | — | US | disclosed |
| US-20130197105-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2002083113-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL AND A STEROID SUCH AS E.G. BUDESONIDE OR FLUTICASONE FOR DELIVERY INTO THE LUNGS VIA NEBULIZATION | DEY, L.P. (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083079-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL FOR DELIVERY TO THE LUNGS VIA NEBULIZATION | DEY, L.P. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-5708036-A | Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol | SAVOR, EVELYN (LYN) P. | 1998-01-13 | — | — | US | disclosed |
| US-5686413-A | FOR IMPROVING GROWTH PROMOTION OR FEED EFFICIENCY | ELI LILLY AND COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| US-5025005-A | Preventive or therapeutic agents for circulatory diseases, allergic disorders; antineoplastic agent; inhibitor for platelet activating factor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-06-18 | — | — | US | disclosed |
| US-5011993-A | Method for the preparation of α1 [[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol | SCHERING CORPORATION (US) | 1991-04-30 | — | — | US | disclosed |
| US-5011993-A | Method for the preparation of α1 [[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol | SCHERING CORPORATION (US) | 1991-04-30 | — | — | US | disclosed |
| US-4952729-A | Intermediates in the preparation of alpha1(((1,1-dimethylethyl) amino) methyl)-4-hydroxy-1,3-benzenedimethanol | SCHERING-PLOUGH CORP. (US) | 1990-08-28 | — | — | US | disclosed |
| US-4737518-A | ANTIALLERGENS, ANTINEOPLASTICS, ANTICOAGULANTS, CIRCULATORY DISEASES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-04-12 | — | — | US | disclosed |
| EP-0259159-A2 | Method for the preparation of alpha1- [[(1,1-Dimethylethyl) amino] methyl]-4-hydroxy-1,3-benzenedimethanol, and intermediates used in its preparation | SCHERING CORPORATION (US) | 1988-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303498-A1 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid | STS, SAE1, PDCD2L | ADRB2 1076/4885HIF1A 4648/4885ADRB1 805/4885 |
| US-20130197105-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | DSP, DSC1, SAE1 | ADRB2 1196/4885HIF1A 4847/4885ADRB1 1315/4885 |
| US-10799599-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | STS, SAE1, PDCD2L | ADRB2 1076/4885HIF1A 4648/4885ADRB1 805/4885 |
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | STS, SAE1, PDCD2L | ADRB2 1076/4885HIF1A 4648/4885ADRB1 805/4885 |
| US-10207008-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | STS, SAE1, PDCD2L | ADRB2 1076/4885HIF1A 4648/4885ADRB1 805/4885 |
| US-10159752-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | STS, SAE1, PDCD2L | ADRB2 1076/4885HIF1A 4648/4885ADRB1 805/4885 |
| US-10117940-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | DSP, DSC1, SAE1 | ADRB2 1196/4885HIF1A 4847/4885ADRB1 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.